Loading…
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $129M | $16M | $17M | $13M | 22.7% | 29.9% | 103.3% |
| 2024 | $100M | $9M | $9M | $12M | 18.5% | 19.2% | - |
| 2023 | $84M | $-4M | $-5M | $7M | -17.4% | 16.0% | - |
| 2022 | $72M | $-17M | $-17M | $-15M | -57.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 72.05 | 83.57 | 99.60 | 129.42 |
| Cost Of Revenue | 29.25 | 32.79 | 38.01 | 46.23 |
| Gross Profit | 42.80 | 50.78 | 61.59 | 83.19 |
| Operating Expense | 61.42 | 56.38 | 53.86 | 68.89 |
| Operating Income | -18.63 | -5.60 | 7.73 | 14.30 |
| EBITDA | -16.74 | -3.89 | 9.21 | 15.75 |
| EBIT | -18.63 | -5.60 | 7.73 | 14.30 |
| Pretax Income | -16.54 | -4.94 | 8.86 | 18.19 |
| Tax Provision | 0 | 0 | 0.30 | 0.81 |
| Net Income | -16.54 | -4.94 | 8.55 | 17.38 |
| Net Income Common Stockholders | -16.54 | -4.94 | 8.55 | 17.38 |
| Total Expenses | 90.68 | 89.17 | 91.87 | 115.13 |
| Interest Income | 0 | 0.66 | 1.13 | 2.13 |
| Research And Development | 4.83 | 4.96 | 6.02 | 6.33 |
| Selling General And Administration | 56.60 | 51.42 | 47.84 | 62.56 |
| Normalized EBITDA | -16.74 | -3.89 | 9.21 | 13.76 |
| Normalized Income | -16.54 | -4.94 | 8.55 | 15.49 |
| Basic EPS | -0.24 | -0.07 | 0.11 | 0.22 |
| Diluted EPS | -0.24 | -0.07 | 0.11 | 0.20 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0.09 |
| Tax Rate For Calcs | 0 | 0 | 0.03 | 0.04 |
| Total Unusual Items | 0 | 0 | 0 | 1.98 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | 1.98 |
| Net Income From Continuing Operation Net Minority Interest | -16.54 | -4.94 | 8.55 | 17.38 |
| Reconciled Depreciation | 1.88 | 1.71 | 1.48 | 1.45 |
| Reconciled Cost Of Revenue | 29.25 | 32.79 | 38.01 | 46.23 |
| Net Interest Income | 0 | 0.66 | 1.13 | 2.13 |
| Net Income From Continuing And Discontinued Operation | -16.54 | -4.94 | 8.55 | 17.38 |
| Total Operating Income As Reported | -18.63 | -5.60 | 7.73 | 16.28 |
| Diluted Average Shares | 69.73 | 74.98 | 78.12 | 85.44 |
| Basic Average Shares | 69.73 | 74.98 | 75.93 | 79.18 |
| Diluted NI Availto Com Stockholders | -16.54 | -4.94 | 8.55 | 17.38 |
| Net Income Including Noncontrolling Interests | -16.54 | -4.94 | 8.55 | 17.38 |
| Net Income Continuous Operations | -16.54 | -4.94 | 8.55 | 17.38 |
| Other Income Expense | 2.08 | 0 | 0 | 1.77 |
| Other Non Operating Income Expenses | 2.08 | 0 | 0 | -0.21 |
| Special Income Charges | 0 | 0 | 0 | 1.98 |
| Other Special Charges | 0 | 0 | 0 | -1.98 |
| Net Non Operating Interest Income Expense | 0 | 0.66 | 1.13 | 2.13 |
| Total Other Finance Cost | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 0 | 0.66 | 1.13 | 2.13 |
| Selling And Marketing Expense | 28.31 | 26.44 | 29.47 | 35.51 |
| General And Administrative Expense | 28.29 | 24.98 | 18.38 | 27.06 |
| Other Gand A | 28.29 | 24.98 | 18.38 | 27.06 |
| Operating Revenue | 72.05 | 83.57 | 99.60 | 129.42 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Niagen Bioscience, Inc.this co. | NAGE | $381M | 23.80↓ discount | 4.97 | 22.7% | 21.23 |
| TruBridge, Inc. | TBRG | $386M | 88.72 | 2.10 | 2.4% | 13.37 |
| Weave Communications, Inc. | WEAV | $385M | - | 4.61 | -34.1% | -18.58 |
| Cerus Corporation | CERS | $385M | - | 5.75 | -24.1% | -52.90 |
| Puma Biotechnology, Inc. | PBYI | $381M |
| 12.26 |
| 2.89 |
| 23.9% |
| 6.57 |
| Viemed Healthcare, Inc. | VMD | $381M | 26.73 | 2.66 | 10.4% | 7.66 |
| Rocket Pharmaceuticals, Inc. | RCKT | $380M | - | 1.36 | -80.5% | -0.98 |
| OrthoPediatrics Corp. | KIDS | $376M | - | 1.06 | -11.4% | -53.45 |
| NRC Health | NRC | $373M | 42.41 | 26.76 | 82.9% | 12.41 |
| Peer Median | - | 34.57 | 2.77 | -4.5% | 2.79 | |